Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Meric‐Bernstam, Funda; Makker, Vicky; Oaknin, Ana; Oh, Do‐Youn; Banerjee, Susana; González-Martı́n, Antonio; Hae Jung, Kyung; Ługowska, Iwona; Manso, Luís; Manzano, Aránzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Ma, Yan; D. Puvvada, Soham; J. Shire, Norah; Lee, Jung‐Yun

doi:10.1200/jco.23.02005

Public

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Published in Journal of Clinical Oncology • Oct 23, 2023

Authors:

Funda Meric‐Bernstam

Vicky Makker

Ana Oaknin

Abstract

PURPOSE: Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. Treatments are limited for other HER2-expressing solid tumors. METHODS: This open-la...

Subject

Medicine

Internal medicine

Trastuzumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!